Omeros Corporation
OMER · Nasdaq · United States
Share price · OMER
Loading chart…
Prices are end-of-day (EOD), delayed by 24 hours · Adjusted for stock splits · Data via Databento
Unusual price moves
Days when OMER's shares moved far more than they usually do, with what was announced that day or the session before. An announcement on the same day does not show that it caused the move. How the days are picked
- 17 Nov 2026-16.5%
- 16 Oct 2026-13.8%
- 13 Aug 2026+26.5%
- 27 Jul 2026+15.8%
Nothing announced by OMER that day or the session before.
- 6 Jul 2026+11.4%
- 29 Jun 2026+14.3%
Nothing announced by OMER that day or the session before.
- 26 Jun 2026-19.1%
- 12 Jun 2026-14.2%
Nothing announced by OMER that day or the session before.
- 27 Apr 2026+8.9%
Nothing announced by OMER that day or the session before.
- 2 Apr 2026-9.8%
Nothing announced by OMER that day or the session before.
Share of unusual movement by asset
For each asset, the share of OMER's own-move activity since 2 Jul 2024 that fell on the session of one of the asset's own announcements or the session after it. Large moves count for much more than small ones. A session shared by several assets is split between them. A share is shown once an asset has at least 8 event days; below that, its events are listed instead.
Assets
(1 total)
| Target & Modality | |||
|---|---|---|---|
narsoplimab(Yartemlea) | Approved | MASP-2Monoclonal antibody | Thrombotic Microangiopathy |
Upcoming events
No upcoming trial completions or earnings dates on record for this company's assets.
Regulatory and conference events
(1)
Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.
Recent
Financial reports
Quarterly & interim (15)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q2 | $29M | $14M | $2.0M+ $130M short-term inv. | —$4.2M operating cash flow | report ↗ |
View 14 more
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2026-Q1 | $9.9M | $13M | $1.9M+ $133M short-term inv. | —-$15M operating cash flow | report ↗ |
| 2025-Q3 | — | $16M | $2.4M+ $34M short-term inv. | $31M-$18M operating cash flow | report ↗ |
| 2025-Q2 | — | $22M | $1.9M+ $27M short-term inv. | $25M-$22M operating cash flow | report ↗ |
| 2025-Q1 | $0 | $24M | $4.3M+ $48M short-term inv. | $33M-$36M operating cash flow | report ↗ |
| 2024-Q3 | — | $24M | $1.5M+ $122M short-term inv. | $32M-$32M operating cash flow | report ↗ |
| 2024-Q2 | — | $45M | $2.1M+ $157M short-term inv. | $56M-$46M operating cash flow | report ↗ |
| 2024-Q1 | — | $27M | $1.8M+ $229M short-term inv. | $37M-$42M operating cash flow | report ↗ |
| 2023-Q3 | — | $32M | $31M+ $280M short-term inv. | $38M-$33M operating cash flow | report ↗ |
| 2023-Q2 | — | $30M | $6.6M+ $335M short-term inv. | $37M-$32M operating cash flow | report ↗ |
| 2023-Q1 | — | $25M | $3.8M+ $368M short-term inv. | $34M$175M operating cash flow | report ↗ |
| 2022-Q3 | — | $39M | $146M+ $75M short-term inv. | $17M-$26M operating cash flow | report ↗ |
| 2022-Q2 | — | $24M | $14M+ $108M short-term inv. | $31M-$19M operating cash flow | report ↗ |
| 2022-Q1 | — | $24M | $9.0M+ $133M short-term inv. | $33M-$15M operating cash flow | report ↗ |
| 2021-Q3 | $30M | $27M | $7.4M+ $43M short-term inv. | $23M-$24M operating cash flow | report ↗ |
Annual history (5 years)
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2025-FY | — | $81M | $9.7M+ $162M short-term inv. | $0.8M-$116M operating cash flow | report ↗ |
For fiscal 2025, Omeros Corporation did not disclose revenue. R&D spend was $81.3M, down 32.0% YoY. The company reported cash and equivalents of $9.66M, a net loss of $3.35M, and a quarterly net burn of $3.35M.
Key reported events include FDA approval of YARTEMLEA (narsoplimab-wuug) for TA-TMA in December 2025, with commercial distribution beginning in January 2026, and a marketing authorization application under EMA review. In November 2025, Omeros closed an asset purchase and license agreement with Novo Nordisk for zaltenibart, receiving a $240.0M upfront payment with eligibility for up to $1.8B in milestones plus tiered royalties. Pipeline updates include planned Phase 2 trials in ARDS, preparation for OMS1029 Phase 2 development, a NIDA-funded OMS527 Phase 1b study, and ongoing IND-enabling work for OncotoX-AML.
View 4 more years
| Period | Revenue | R&D | Cash & equiv. | Net loss / qtr | Filing |
|---|---|---|---|---|---|
| 2024-FY | — | $120M | $3.4M+ $87M short-term inv. | $39M-$149M operating cash flow | report ↗ |
| 2023-FY | — | $115M | $7.1M+ $165M short-term inv. | $29M$75M operating cash flow | report ↗ |
| 2022-FY | — | $113M | $11M+ $184M short-term inv. | —-$86M operating cash flow | report ↗ |
| 2021-FY | — | $119M | $101M+ $56M short-term inv. | —-$110M operating cash flow | report ↗ |
Insider transactions
Open-market activity, trailing 12 months: 0 purchases ($0), 14 sales ($3.0M). Awards, option exercises and tax-withholding rows are listed below but excluded from these totals.
| Source | ||||||
|---|---|---|---|---|---|---|
| 2026-10-28 | Demopulos Gregory A MD · director, Chairman, CEO & President | Award / grant (derivative) | 500,000 | — | — | Form 4 |
| 2026-09-23 | Borges David J. · VP, Finance & CAO | Option exercise | 10,000 | $15.58 | $156K | Form 4 |
| 2026-09-23 | Borges David J. · VP, Finance & CAO | Open-market sale | 10,000 | $20.95 | $210K | Form 4 |
| 2026-09-23 | Borges David J. · VP, Finance & CAO | Option exercise (derivative) | 10,000 | — | — | Form 4 |
| 2026-09-22 | Borges David J. · VP, Finance & CAO | Option exercise | 5,000 | $3.93 | $20K | Form 4 |
| 2026-09-22 | Borges David J. · VP, Finance & CAO | Option exercise | 5,000 | $2.94 | $15K | Form 4 |
| 2026-09-22 | Borges David J. · VP, Finance & CAO | Open-market sale | 10,000 | $20.95 | $210K | Form 4 |
| 2026-09-22 | Borges David J. · VP, Finance & CAO | Option exercise (derivative) | 5,000 | — | — | Form 4 |
Institutional holders
From SEC Form 13F filings for the quarter ended 2026-03-31 (filed up to 45 days later). 160 reporting institutions held 30.8M shares ($285.6M, 42.6% of shares outstanding).
| # | Institution | Shares | Value |
|---|---|---|---|
| 1 | BlackRock, Inc. | 5,309,626 | $56.1M |
| 2 | VANGUARD CAPITAL MANAGEMENT LLC | 2,983,259 | $31.5M |
| 3 | UBS Group AG | 2,340,731 | $24.7M |
| 4 | STATE STREET CORP | 1,919,575 | $20.3M |
| 5 | STIFEL FINANCIAL CORP | 1,831,585 | $19.3M |
| 6 | GEODE CAPITAL MANAGEMENT, LLC | 1,752,323 | $18.5M |
| 7 | Corient Private Wealth LLC | 801,411 | $8.5M |
| 8 | VANGUARD PORTFOLIO MANAGEMENT LLC | 718,675 | $7.6M |
| 9 | CHARLES SCHWAB INVESTMENT MANAGEMENT INC | 582,512 | $6.2M |
| 10 | BANK OF MONTREAL /CAN/ | 568,426 | $6.0M |
| 11 | NORTHERN TRUST CORP | 563,867 | $6.0M |
| 12 | VANGUARD FIDUCIARY TRUST CO | 492,345 | $5.2M |
| 13 | SUSQUEHANNA INTERNATIONAL GROUP, LLP | 485,030 | $5.1M |
| 14 | MILLENNIUM MANAGEMENT LLC | 410,609 | $4.3M |
| 15 | MORGAN STANLEY | 317,892 | $3.4M |